TY - JOUR T1 - Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy JO - Revista EspaƱola de Medicina Nuclear e Imagen Molecular T2 - AU - Kalender,E. AU - Zeki Celen,Y. AU - Elboga,U. AU - Deniz Demir,H. AU - Yilmaz,M. SN - 2253654X M3 - 10.1016/j.remn.2012.04.007 DO - 10.1016/j.remn.2012.04.007 UR - https://www.elsevier.es/es-revista-revista-espanola-medicina-nuclear-e-125-articulo-lung-metastases-in-patients-with-S2253654X12001163 AB - IntroductionThe most common site of metastases in differentiated thyroid carcinomas is the lungs. In our study, we aimed to determine the ratios of lung metastases in patients with differentiated thyroid carcinoma and response to radioiodine therapy. Material and methodsA total of 542 patients with differentiated thyroid carcinoma who were admitted to our clinic were included in the study. High doses of 131I were administered to the patients with lung metastases. Response to therapy were evaluated with 131I scans and stimulated serum Tg levels were examined at least 6 months after therapy. ResultsLung metastases were detected in 17 (3.1%) of 542 patients with differentiated thyroid carcinoma. Of these patients to whom high doses of 131I therapy were administered, complete response to therapy was obtained in 5 (29.4%), partial response was obtained in 3 (17.6%) and no response could be obtained in 9 (53%) patients. ConclusionAlthough lung metastases from differentiated thyroid carcinomas are rare, those are more common in advanced ages and in males. High doses of 131I therapy may be partially beneficial in these patients. Thus repetition of therapy is frequently required. ER -